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Summary. Nonspecific uptake of radiolabeled monoclonal 
antibodies in normal tissues is a significant problem for tu- 
mor imaging. A potential means of decreasing nonspecific 
antibody binding is to "blockade" nonspecific antibody 
binding sites by predosing with cold, nonspecific isotype- 
matched antibody, before injecting specific antibody. 
Nontumor-specific murine monoclonal antibody LK2H 10 
(IgGl)  or Ab-1 (IgG2a) was given i.v. at doses of 0 to 
3.5 mg to nude mice with xenografts of human melanoma. 
These mice were then given i.v. 4 I~g of 131I anti-high mo- 
lecular weight antigen of melanoma (HMWMAA) mono- 
clonal antibody 763.24T (IgG1) or 225.28S (IgG2a), re- 
spectively. These mice were also given a tracer dose of 125I 
LK2H10 or Ab-1, respectively. Specific tumor uptake of 
anti-HMWMAA antibodies was see in all cases. No drop 
in tumor or nontumor uptake was demonstrated for either 
of the tumor-specific or nonspecific monoclonal antibod- 
ies due to nonspecific monoclonal antibody pretreatment. 
These data suggest that high doses of isotype-matched un- 
labeled nonspecific monoclonal antibody given before ~3~I 
tumor-specific monoclonal antibody, will not enhance ~u- 
mor imaging. 
Introduction 
Nonspecific accumulation of radiolabeled monoclonal an- 
tibodies reactive with tumor-associated antigens, in a va- 
riety of normal tissues is a limitation to their widespread 
clinical utility [16]. While antibody fragments have been 
shown to improve this problem, their production can be 
difficult in some cases, and absolute tumor uptakes are 
generally lower than those of intact antibody [3, 12, 17]. 
Some uptake of intact antibodies to nontarget organs 
may be due to interactions of the F-C portion of IgG an- 
tibodies with cells of the reticuloendothelial system (RES) 
[17]. While antibody fragments eliminate the possibility of 
such F-C interactions, an alternative approach would be to 
saturate or blockade these RES sites (F-C gamma recep- 
tors present in the liver, spleen, lungs, and bone marrow) 
by high doses of unlabeled nonspecific antibody. Three 
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types of F-C gamma receptors have been described, two of 
which have low affinity for monomeric IgG and one of 
which has high affinity [2]. Since different isotypes of 
monoclonal antibodies may potentially have differential 
binding to F-C gamma receptors, such RES blockade 
would seem most effectively mediated by an isotype- 
matched nonspecific antibody. 
There is also a precedent for RES blockade in man, in 
the case of successful treatment with unlabeled nonspecific 
IgG improve platelet survival duration in indiopathic 
thrombocytopenic purpura [8]. The aim of our investiga- 
tion was to determine if "RES blockade" with a high dose 
of unlabeled isotype-matched monoclonal antibody was 
effective in enhancing specific monoclonal antibody local- 
ization (or in decreasing nonspecific organ accumulation 
by F-C gamma blockade) to human melanoma xenografts 
in a nude mouse model of human melanoma. 
Materials and methods 
Monoclonal antibodies. 225.28S (murine IgG2ak) and 
763.24T (murine IgG1K) are reactive with a high molecu- 
lar weight antigen present on the surface of most melano- 
mas [5, 22]. The 225.28S has previously been shown to lo- 
calize largely due to antibody specificity to human mela- 
noma xenografts and has successfully imaged melanoma 
in humans [1, 6, 15]. The AB-1 (murine IgG2ak) is reactive 
with the receptor for the C3d human complement compo- 
nent but is not known to react with murine complement 
determinants [23]. The LK2H10 (murine IgGlk)  is a mon- 
oclonal antibody reactive with chromogranin of human 
origin, but not with mouse determinants [21]. All hybrido- 
mas were grown as ascities in BALB/c mice. The IgG2a 
antibodies were purified by staphylococcal protein A 
chromatography, while the IgGls  were purified by DEAE 
chromatography [4, 17]. The purity of preparations was 
confirmed by 7.5% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis [9]. 
Antibody labeling. The iodobead method was used to label 
each monoclonal antibody [13]. In general 2 iodobeads 
and 1 mCi of ~31I o r  125I were used to label 50-100 gg of 
purified antibody. Free iodine was removed by separation 
over a Biogel P-60 sizing column (Biorad). Yields of 
40%-70% were typical, with a final specific activity of ap- 
proximately 4 - 7  p.Ci/gg. The lack of free iodine contami- 
nation in the preparations was confirmed by silica gel 
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thin- layer  chromatography  using 50% ethanol and 50% 
ethyl acetate as a solvent [20]. Labeled ant ibodies  were 
tested for b inding by a direct  cell b inding  assay to HTB-63 
me lanoma  cells in which 5 × 106 ceils were reacted with in- 
creasing dilutions of  an t ibody  in efforts to achieve antigen 
excess. These binding assays were carried out at 37 °C for 
1 h [10, 201. 
Animal model. Female  n u / n u  mice 4 to 6 weeks old  were 
injected s.c. with 10 × 106 HTB-63 human me lanoma  cells. 
Solid tumors  were pa lpab le  3 - 4  weeks later. When  tumors  
were at least 5 mm in diameter ,  mice were studied. 
Localization study. The I g G 2 a K  monoc lona l  an t ibody  
AB-1 was given i.v. to groups of  tumor-bear ing  animals  at 
doses of  0 l-tg (normal  saline), 500 p-g, and  2500 l-tg. Ap-  
p rox imate ly  1 h later these doses were fol lowed by an i.v. 
inject ion of  a mixture of  30 p-C± of  1311 225.28S and 15 p-C± 
of  1251 AB-I  (4 and 2 p.g, respectively). Animals  were sacri- 
ficed 7 days after injection and tissues weighed and coun- 
ted. After  correct ion for spi l lover and  physical  decay,  per- 
cent k i logram dose per  gram and t u m o r / n o n t u m o r  ratios 
were de termined using s tandard  tissue processing tech- 
niques [18, 19]. 
A similar  exper iment  was conducted  for the IgG1 an- 
t ibody,  LK2-H10. This unlabeled  murine  monoc lona l  an- 
t ibody,  without  specificity for mouse proteins,  was given 
to groups of  tumor-bear ing  animals  at dose of  0 txg (nor- 
mal saline) 1000 l.tg, and 3500 btg. Then 1 h later,  animals  
were given a dual- label  inject ion of  30 p-C± of  1311 763.24T 
(ant i -melanoma)  and 15 gCi o f  1251 LK2H10 i.v. Animals  
were then main ta ined  on Lugol 's  iodine,  with sacrifice and 
tissue counting 8 days after injection. 
Statistical analysis was by the Student ' s  t-test with cor- 
rection for small sample  sizes and ANOVA.  
Results 
The HTB-63 ant igen-posi t ive me lanoma  target cells of  
763.24T and 225.28S showed strong specific b inding  with 
immunoreac t ive  fractions of  48% and 58% respectively af- 
ter a 1-h incubation.  AB-1 and LK2H10 by contrast  had 
only nonspecif ic  b inding  to HTB-63 cells of  1.7% and 0.2% 
of  input  counts. 
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Fig. 1. Mean±SEM of tumor/nontumor uptake ratios (% kg 
dose/g tumor/% kg dose/g nontumor) for 225.28S and Ab-I 7 
days after injection. Note the lack of significant difference within 
the specific antibody and the nonspecific antibody groups. By 
contrast, the localization of 225.28S was significantly better than 
that of Ab-1 (P<0.01) 
Tissue distr ibut ions 7 days fol lowing the i.v. injection 
of  131I 225.28S and IzsI AB-1 are shown in Fig. 1 as indica-  
ted by t u m o r / n o n t u m o r  ratios. There was no al terat ion in 
the biodis t r ibut ion of  the specific an t i -melanoma an t ibody  
despi te  the high-dose nonspecif ic  an t ibody  pre t rea tment  
(Fig. 1). No change in the biodis t r ibut ion of  Ab-1 nonspe-  
cific an t ibody  was seen either ( P =  NS by ANOVA).  Tu- 
m o r / n o n t u m o r  ratios were significantly higher for the 
225.28S than for the Ab-1 (P<0.01).  
Tissue distr ibut ions fol lowing the i.v. injection of  1311 
763.24T and lZSI LK2H10 are shown as t u m o r / n o n t u m o r  
ratios in Fig. 2. There was no al terat ion ( P =  NS by A N O -  
VA) in the dis tr ibut ion o f  these IgG 1 k a p p a  ant ibodies  
fol lowing a variety of  levels of  pre t rea tment  with nonspe-  
cific IgG1 (anti-CG). Again,  t u m o r / n o n t u m o r  ratios were 
significantly higher for the 763.24T-specific monoclona l  
an t ibody  than for the LK2H10 ( P <  0.01), indicat ing spe- 
cific tumor  uptake of  these reagents. Table  1 shows b lood  
uptake  of  the two ant ibodies  as related to predose  of  cold 
ant ibody.  Table  2 indicates uptake to tumor,  while Table 3 
shows mean tumor  weights. 
Table I. % Kg dose/g in blood ± SD 7 to 8 days after injection 
Ab- 1 225.28S LK2H 10 763.24T 
Predose = saline 
Isotype-matched low-dose nonspecific 
monoclonal antibody 
Isotype-matched high-dose nonspecific 
monoclonal antibody 
0.197 ± 0.078 0.047 _+ 0.028 0.104 ± 0.003 0.081 ± 0.0008 (n = 5) 
0.312+0.061 0.110±0.050 0.099___0.010 0.081 ±0.008 (n = 7) 
0.210 + 0.04 0.073 ± 0.018 0.106 ± 0.034 0.086 ± 0.028 (n = 5) 
Table 2. % Kg dose/g injected reaching tumor ± SEM 7 to 8 days after injection 
Ab- 1 225.28S LK2H 10 763.24T 
Saline 0.078 ___ 0.016 0.051 + 0.018 0.020 ± 0.000 0.043 ± 0.001 (n = 5) 
Low 0.078 _+ 0.005 0.050 ± 0.010 0.024 _ 0.003 0.043 ± 0.010 (n = 7) 
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Fig. 2. Mean+SEM of tumor/nontumor uptake ratios for 763 
and LK2H10 antibodies 8 days after injection. Note the lack of 
significant difference within the specific antibody and the nonspe- 
dfic antibody groups. By contrast, the localization of the specific 
763 was significantly better than that of the nonmelanoma-sPeci- 
fic LKH210 
Table 3. Mean tumor weights (g) + SEM at sacrifice 
Predose Ab- 1/225.28S LK2H 10/763.24T 
Saline 0.611 + 0.048 0.218 + 0.018 
Low 0.390 + 0.113 0.265 + 0.144 
High 0.340+0.113 0.132+0.018 
No significant difference existed among the tumor weights of the 
IgG2a (Ab-1/225.28S) groups or among the IgG1 (LK2H10/ 
763.24T) groups by ANOVA 
Discuss ion  
These studies indicated that no alteration is seen in the 
biodistribution of two different anti-melanoma monoclon- 
al antibodies with specificity for the same high molecular 
weight antigen of human melanoma following varying le- 
vels of predosing with nonspecific isotype-matched mu- 
rine monoclonal antibodies. The study also showed no vis- 
ible alteration in the biodistribution of the nonspecific an- 
tibodies. This result is of considerable interest, in that if 
less specific antibody uptake was to have been seen in the 
liver, lung, and spleen, following nonspecific antibody 
pretreatment, then this approach might diminish or elimi- 
nate the need for antibody fragmentation for imaging pur- 
poses. In many systems, this latter approach has produced 
higher target/nontarget ratios then the use of comparable 
intact antibodies [17]. This approach is not always appli- 
cable or convenient, as some monoclonal antibodies are 
difficult or impossible to digest to F(ab')2 fragments in re- 
plicable or acceptable yields such as IgM and IgG2bs [12]. 
It is conceivable that even at the high doses of anti- 
body used (3.5 mg in a 20 g mouse extrapolates to 12.25 g 
in a human) that the F-C receptors in the organs of interest 
are not fully saturated. However, with polyclonal immune 
globulin, doses in the gra m range have been given and ap- 
parently have resulted in RES blockade [2, 8]. With a mon- 
oclonal anti-F-C receptor antibody, doses of 25-42 mg 
have shown a transient effect [2]. It is probable that doses 
of antibody larger than 12 g would be unrealistic and cer- 
tainly expensive in man. It is also possible that if F-C 
blockade was achieved, diminished F-C binding may not 
be the sole reason for the higher target/nontarget levels 
achieved in vivo by antibody fragments. It is possible that 
the smaller size of the F(ab')2 fragments versus intact anti- 
body may contribute to improved tumor/nontumor ratios 
[7, 17]. Nonetheless F-C binding and its abgroation are 
certainly likely to be very imprtant since preliminary data 
suggest that deletions of selective domains of the mouse 
immunoglobulin molecule (C2H or C3H) will result in be- 
havior similar to that of the F(ab')2 fragments, with faster 
clearance and higher target/nontarget levels of antibody 
[14]. This was not seen in our study of antibody predosing, 
where despite high predose levels, no difference in tissue 
levels including blood levels of monoclonal antibodies 
were seen 7 days after injection. While it is conceivable 
that had time points earlier than 7 days after injection 
been examined, more of an effect would have been seen 
with predosing, 7 to 8 days was chosen for sacrific as in 
general delays in this range following monoclonal injec- 
tion result in superior tumor/nontumor uptake then earlier 
sampling [17]. Of possible relevance is the suggestion that 
intact antibody with F-C present may be interacting with 
circulating antigen in tumor systems and result in RES up- 
take [7]. The antigen recognized by 225.28S is not heavily 
shed (Wilson BS unpublished data) and thus immune com- 
plexe uptake may not be as likely in this system. 
Our study demonstrated that even extremely high 
doses of nonspecific monoclonal antibody given shortly 
before the administration of specific monoclonal antibody 
do not significantly alter the specific or nonspecific radio- 
iodinated monoclonal antibody delivery to the tumor tar- 
get or to nontarget tissues in this human melanoma xeno- 
graft system. Results with biosynthetically labeled or me- 
tal-chelated antibody might also be different, as a satu- 
rable hepatic receptor for Ill in antibodies may be present 
[11]. It is also conceivable that earlier sacrifice times might 
have demonstrated a reduction in nontumor tissue uptake 
in labeled antibody with predosing, however since maxi- 
mal relative uptake of antibody to tumor is late, the lack of 
any change in late uptake makes earlier uptake differences 
improbable. The evaluation of differences at early time 
points may be of interest, however in view of the use of 
shorter-lived isotopes than iodine in imaging studies. An 
awareness of this phenomenon of nonenhancement of rel- 
ative tumor uptake with iodinated antibodies should allow 
for the more rational design of clinical studies and may 
spare patients unnecessary exposure to high levels of un- 
labeled nonspecific foreign antibody molecules. 
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